Serum long acting thyroid stimulator (LATS) and LATS-protector (LATS-P) in Graves’ disease associated with localized myxedema
Authors:
- 3 April 1984
- journal article
- Published by Springer Nature in Journal of Endocrinological Investigation
- Vol. 7 (2) , 151-156
Abstract
When localized myxedema occurs in Graves’ disease, there is often very high serum long acting thyroid stimulator (LATS) activity. However, this association is not invariable and no pathogenetic role for this IgG associated activity is known. Serum LATS protector (LATS-P) is a closely related IgG activity which is present in the majority of cases of untreated Graves’ disease. It usually coexists in LATS positive sera in a substantially greater concentration. Its association with localized myxedema has not been studied, nor have serial studies been performed on this activity during the clinical course of the disease. Fourteen patients (13 females, 1 male) with localized myxedema and a history of Graves’ disease were examined. In 13 serum LATS was detectable with a wide range of activity from 2.4 to 1,000 units/ml. Serum LATS-P was detected in all including the LATS negative patient with a range of activity from 46 to 4,068 units/ml. Serial studies for at least 2 years were conducted in 8 patients. In two there was no change in either skin lesions or in serum LATS and LATS-P. In 6 the skin lesions partially or completely resolved. In 5 this was associated with statistically significant falls in serum LATS and LATS-P but in one no significant change occurred. The study demonstrated the high prevalence of LATS and LATS-P in localized myxedema. I n the sole LATS negative patient there was a high concentration of LATS-P. The role of these activities in the pathogenesis of the disease remains unknown but in serial studies falls in activity were usually associated with clinical improvement.Keywords
This publication has 14 references indexed in Scilit:
- LONG‐ACTING THYROID STIMULATOR (LATS) AND LONG ACTING THYROID STIMULATOR PROTECTOR (LATS‐P) IN UNTREATED THYROTOXICOSISClinical Endocrinology, 1981
- Successful treatment of exophthalmos and pretibial myxoedema with plasmapheresis.BMJ, 1979
- Stimulation of Fibroblast Biosynthetic Activity by Serum of Patients with Pretibial MyxedemaJournal of Investigative Dermatology, 1978
- SOME FACTORS AFFECTING THE DETECTION OF LONG-ACTING THYROID STIMULATOR PROTECTOR USING THE McKENZIE BIOASSAYJournal of Endocrinology, 1974
- THE INTERACTION OF THE LONG-ACTING THYROID STIMULATOR (LATS) WITH THYROID TISSUE IN VITROJournal of Endocrinology, 1970
- Relationship of long-acting thyroid stimulator to the clinical features and course of Graves' diseaseThe American Journal of Medicine, 1967
- Thyrotropin and Long-Acting Thyroid Stimulator Assays in Thyroid DiseaseThe Journal of Clinical Endocrinology & Metabolism, 1965
- Parallel Assays of Thyrotrophin, Long-Acting Thyroid Stimulator and Exophthalmos-Producing Substance in Endocrine Exophthalmos and Pretibial MyxedemaThe Journal of Clinical Endocrinology & Metabolism, 1964
- Isolation and Identification of the Long-Acting Thyroid Stimulator and Its Relation to Hyperthyroidism and Circumscribed Pretibial Myxedema1The Journal of Clinical Endocrinology & Metabolism, 1964
- Hyperthyroidism, Pretibial Myxedema, and ClubbingArchives of Dermatology, 1963